Clinical Efficacy: Solid Tumors

Breast Cancer & Melanoma

References: 1. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2017. 2. Sondak V, King DW, Zager JS, et al. Combined analysis of Phase III trials evaluating Tc99m tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20:680-8. 3. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [99mTc] tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two Phase 3 trials. Ann Surg Oncol. 2013; doi 10.1245/s10434-013-2887-8. 4. Data on file, Cardinal Health 5. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23 (30):7703-7720.

Squamous Cell Carcinoma

References: 1. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2017. 2. Data on file, Cardinal Health 3. Lai SW. Receptor-targeted 99mTc-tilmanocept for sentinel lymph node biopsy (SLNB) in HNSCC: predictive utility vs elective neck dissection. Presented at 6th European Congress on Head and Neck Oncology. Liverpool, UK. April 24-26, 2014. Abstract. 4. Alkureishi LW, Ross GL, Shoaib T, et al. Sentinel Node Biopsy in Head and Neck Squamous Cell Cancer: 5-Year Follow-Up of a European Multicenter Trial. Ann Surg Oncol. 2010; 17:2459–2464.